Clinical Trial ProgressPatient enrollment in the Phase 2 IST testing AGENT-797 in patients with second-line gastric cancer has exceeded expectations, and initial data will be presented at a medical meeting.
Funding And Financial StrategyAcceptance of funding from NIAID for the upcoming GvHD study is considered a positive development for the company.
Immunotherapy EffectivenessRecent data from the Phase 2 trial in refractory gastroesophageal cancer showed promising increases in immune cell activity, indicating potential effectiveness of the treatment.